Abstract
Forty-three women with acute, symptomatic urinary tract infections were randomized to receive either norfloxacin (400 mg) twice daily or trimethoprim-sulfamethoxazole (160-800 mg) twice daily for 10 days. Of the 43 patients, 7 (16%) had low-count bacteriuria and pyuria and were included in the evaluation. Escherichia coli was isolated in 72% of the infections, whereas coagulase-negative staphylococci were isolated in 14%. All isolates were susceptible to the assigned study drug. The MICs for 90% of the strains susceptible to norfloxacin and trimethoprim-sulfamethoxazole were less than or equal to 2 and less than or equal to 0.8-16 micrograms/ml, respectively. The cure rates for norfloxacin and trimethoprim-sulfamethoxazole were 95 and 90%, respectively. There were 17 patients with presumptive upper tract infections; only 1 of these relapsed after therapy. The effects on the periurethral flora were similar in both groups, but the infecting organism was eradicated from the fecal flora in 93% of the patients treated with norfloxacin and in 57% of the patients treated with trimethoprim-sulfamethoxazole. More early reinfections occurred in the trimethoprim-sulfamethoxazole group, with resistant organisms appearing in urine and in the periurethral and fecal flora in all cases. Three patients in each group experienced adverse clinical effects, but these were more severe in the trimethoprim-sulfamethoxazole group. No adverse hematological or biochemical changes were noted. From these results, we concluded that norfloxacin is at least as effective as trimethoprim-sulfamethoxazole in the therapy of acute, symptomatic urinary tract infections in women.
Full text
PDF



Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brumfitt W., Pursell R. Double-blind trial to compare ampicillin, cephalexin, co-trimoxazole, and trimethoprim in treatment of urinary infection. Br Med J. 1972 Jun 17;2(5815):673–676. doi: 10.1136/bmj.2.5815.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Buckwold F. J., Ludwig P., Harding G. K., Thompson L., Slutchuk M., Shaw J., Ronald A. R. Therapy for acute cystitis in adult women. Randomized comparison of single-dose sulfisoxazole vs trimethoprim-sulfamethoxazole. JAMA. 1982 Apr 2;247(13):1839–1842. [PubMed] [Google Scholar]
- Buckwold F. J., Ronald A. R., Harding G. K., Marrie T. J., Fox L., Cates C. Biotyping of Escherichia coli by a simple multiple-inoculation agar plate technique. J Clin Microbiol. 1979 Sep;10(3):275–278. doi: 10.1128/jcm.10.3.275-278.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Downs J., Andriole V. T., Ryan J. L. In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Apr;21(4):670–672. doi: 10.1128/aac.21.4.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gadebusch H. H., Shungu D. L., Weinberg E., Chung S. K. Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents. Infection. 1982 Jan;10(1):41–44. doi: 10.1007/BF01640837. [DOI] [PubMed] [Google Scholar]
- Giamarellou H., Tsagarakis J., Petrikkos G., Daikos G. K. Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections. Eur J Clin Microbiol. 1983 Jun;2(3):266–269. doi: 10.1007/BF02029530. [DOI] [PubMed] [Google Scholar]
- Guerra J. G., Falconi E., Palomino J. C., Benavente L., Antunez de Mayolo E. Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections. Eur J Clin Microbiol. 1983 Jun;2(3):260–265. doi: 10.1007/BF02029529. [DOI] [PubMed] [Google Scholar]
- Haase D., Urias B., Harding G., Ronald A. Comparative in vitro activity of norfloxacin against urinary tract pathogens. Eur J Clin Microbiol. 1983 Jun;2(3):235–241. doi: 10.1007/BF02029524. [DOI] [PubMed] [Google Scholar]
- Harding G. K., Buckwold F. J., Marrie T. J., Thompson L., Light R. B., Ronald A. R. Prophylaxis of recurrent urinary tract infection in female patients. Efficacy of low-dose, thrice-weekly therapy with trimethoprim-sulfamethoxazole. JAMA. 1979 Nov 2;242(18):1975–1977. [PubMed] [Google Scholar]
- Harding G. K., Marrie T. J., Ronald A. R., Hoban S., Muir P. Urinary tract infection localization in women. JAMA. 1978 Sep 8;240(11):1147–1151. [PubMed] [Google Scholar]
- Harding G. K., Ronald A. R. A controlled study of antimicrobial prophylaxis of recurrent urinary infection in women. N Engl J Med. 1974 Sep 19;291(12):597–601. doi: 10.1056/NEJM197409192911203. [DOI] [PubMed] [Google Scholar]
- Harding G. K., Ronald A. R. Clinical experiences: genitourinary infections. A. Infections of the urinary tract. Efficacy of trimethoprim-sulfamethoxazole in bacteriuria. J Infect Dis. 1973 Nov;128(Suppl):641–p. [PubMed] [Google Scholar]
- Harding G. K., Ronald A. R., Nicolle L. E., Thomson M. J., Gray G. J. Long-term antimicrobial prophylaxis for recurrent urinary tract infection in women. Rev Infect Dis. 1982 Mar-Apr;4(2):438–443. doi: 10.1093/clinids/4.2.438. [DOI] [PubMed] [Google Scholar]
- Khan M. Y., Gruninger R. P., Nelson S. M., Klicker R. E. Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates. Antimicrob Agents Chemother. 1982 May;21(5):848–851. doi: 10.1128/aac.21.5.848. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Knothe H. The effect of a combined preparation of trimethoprim and sulphamethoxazole following short-term and long-term administration on the flora of the human gut. Chemotherapy. 1973;18(5):285–296. doi: 10.1159/000221273. [DOI] [PubMed] [Google Scholar]
- Murray B. E., Rensimer E. R., DuPont H. L. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim--sulfamethoxazole. N Engl J Med. 1982 Jan 21;306(3):130–135. doi: 10.1056/NEJM198201213060302. [DOI] [PubMed] [Google Scholar]
- Platt R. Quantitative definition of bacteriuria. Am J Med. 1983 Jul 28;75(1B):44–52. doi: 10.1016/0002-9343(83)90072-4. [DOI] [PubMed] [Google Scholar]
- Preiksaitis J. K., Thompson L., Harding G. K., Marrie T. J., Hoban S., Ronald A. R. A comparison of the efficacy of nalidixic acid and cephalexin in bacteriuric women and their effect on fecal and periurethral carriage of enterobacteriaceae. J Infect Dis. 1981 Apr;143(4):603–608. doi: 10.1093/infdis/143.4.603. [DOI] [PubMed] [Google Scholar]
- Ronald A. R., Harding C. K., Mathias R., Wong C. K., Muir P. Prophylaxis of recurring urinary tract infection in females: a comparison of nitrofurantoin with trimethoprim-sulfamethoxazole. Can Med Assoc J. 1975 Jun 14;112(13 Spec No):13–16. [PMC free article] [PubMed] [Google Scholar]
- Ronald A. R., Turck M., Petersdorf R. G. A critical evaluation of nalidixic acid in urinary-tract infections. N Engl J Med. 1966 Nov 17;275(20):1081–1089. doi: 10.1056/NEJM196611172752001. [DOI] [PubMed] [Google Scholar]
- Stamey T. A., Condy M., Mihara G. Prophylactic efficacy of nitrofurantoin macrocrystals and trimethoprim-sulfamethoxazole in urinary infections. Biologic effects on the vaginal and rectal flora. N Engl J Med. 1977 Apr 7;296(14):780–783. doi: 10.1056/NEJM197704072961403. [DOI] [PubMed] [Google Scholar]
- Stamm W. E., Counts G. W., Running K. R., Fihn S., Turck M., Holmes K. K. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med. 1982 Aug 19;307(8):463–468. doi: 10.1056/NEJM198208193070802. [DOI] [PubMed] [Google Scholar]
- Stamm W. E. Measurement of pyuria and its relation to bacteriuria. Am J Med. 1983 Jul 28;75(1B):53–58. doi: 10.1016/0002-9343(83)90073-6. [DOI] [PubMed] [Google Scholar]
- Swanson B. N., Boppana V. K., Vlasses P. H., Rotmensch H. H., Ferguson R. K. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother. 1983 Feb;23(2):284–288. doi: 10.1128/aac.23.2.284. [DOI] [PMC free article] [PubMed] [Google Scholar]